Blue Grape #1 (CBD): A Comprehensive Strain Guide

Introduction: What Sets Blue Grape #1 (CBD) Apart

Blue Grape #1 (CBD) is a cannabidiol-forward cultivar prized for its vivid berry bouquet, calm-forward effects, and low intoxication profile. While the exact breeder data for this specific phenotype remains limited in public channels, the name and market positioning clearly signal a CBD-dominant selection developed for flavor and composure over potency of THC. For consumers seeking functional relaxation without impairment, this cultivar slots neatly into the modern demand for cannabis that prioritizes wellness and clarity.

Across legal markets, CBD-rich flower typically represents a smaller slice of retail shelves, often under 10–15% of flower SKU rotations, yet maintains steady demand among wellness-focused buyers. Blue Grape #1 (CBD) fits that niche, offering an approachable entry point for people sensitive to THC or those layering cannabinoids for specific therapeutic goals. Its appeal is anchored in consistent calm, an accessible fruit-forward profile, and a smooth mouthfeel more akin to craft herbal tea than classic skunky cannabis.

It is important to note that the strain designation “#1” implies a selected phenotype from a larger population, chosen for uniform expression. Phenotype labels usually reflect stability of terpene aroma, meaningful CBD:THC ratio, and agronomic traits like mildew tolerance. In practice, consumers should always verify potency and terpene data via batch-level certificates of analysis (COAs), because chemotypes can vary between harvests and producers.

Naming, Rarity, and Market Context

The “Blue” and “Grape” cues in the name hint at berry-forward aromatics commonly associated with Blueberry-descended and grape-labeled lines. The “#1” suffix is a breeder signal of a favored selection, often representing stability in the intended cannabinoid ratio and sensory profile. When applied to CBD-dominant lines, this typically suggests the breeder isolated a plant with reliably low THC and a consistent flavor that testers preferred.

Market-wise, CBD flower tends to be overshadowed by THC cultivars in adult-use stores, but it plays an outsized role in medical channels. In many dispensary datasets from 2019–2024, median THC potency for top-selling flower sits around 18–24% THC, while CBD-dominant varieties cluster at <1% THC and 8–18% CBD. That contrast supports a complementary positioning: Blue Grape #1 (CBD) targets functional users seeking symptom relief or daytime relief with minimal cognitive disruption.

Rarity is a factor for consumers. Compared with highly distributed CBD classics like ACDC, Cannatonic, or Harlequin, boutique phenotypes such as Blue Grape #1 (CBD) may appear in limited drops or regional markets. As a result, verifying batch-by-batch lab data is doubly important to ensure that the labeled CBD-forward profile matches the jar you’re purchasing.

History and Breeding Context

Although definitive breeder notes for Blue Grape #1 (CBD) are not broadly published, its profile aligns with common CBD breeding strategies from the mid-2010s onward. Breeders frequently introduce CBD dominance by crossing flavorful terpene-rich parents with CBD-heavy lines like ACDC, Cannatonic, or Candida (CD-1). The goal is to retain the sensory charm of berry and grape cultivars while bringing the THC down to sub-intoxicating levels.

CBD breeding accelerated after 2018 due to the policy shift that normalized hemp cultivation in multiple regions. As growers refined selection, they prioritized tight CBD:THC ratios such as 20:1 or higher to avoid drifting into psychoactive territory. Blue Grape #1 (CBD) appears to be a product of this wave: consumer-friendly taste plus steady CBD outcomes.

Historically, “Blue” and “Grape” lines trace to terpene-rich families noted for linalool, myrcene, and geraniol contributions. Blueberry-descended lines often express anthocyanins in cool grows, yielding violet calyxes and a dessert-like aroma. Grape-labeled varieties typically emphasize floral sweetness and candied fruit notes that remain pleasant even at low temperature vaping settings (e.g., 170–185°C).

Genetic Lineage: Plausible Parentage and Chemotype Targets

Without a breeder-released pedigree, the best way to frame Blue Grape #1 (CBD) lineage is through chemotype logic rather than assumptions. The target chemotype is almost certainly Type III (CBD-dominant), indicated by the explicit “CBD” label and the market fit. Type III flower routinely tests with THC below 1% by weight, often ranging from 0.1–0.8% THC, and CBD in the 8–20% window.

Breeding pathways that yield the Blue Grape profile typically pair a terpene-forward dessert cultivar with a reliable CBD donor. Common CBD donors include ACDC (frequently 15–20% CBD, trace THC), Cannatonic (more variable, often 6–15% CBD), and certain European CBD lines originally selected as hemp but refined for flavor. A selected #1 phenotype would then be stabilized for uniformity in both sensory and potency outcomes.

Chemotype stability matters because CBD:THC ratios can drift across seed populations. In well-executed programs, breeders conduct multi-generational selection to maintain ratios like 20:1 or 15:1. That allows consumers to anticipate mild to negligible intoxication while consistently accessing the desired CBD payload.

Appearance and Morphology

Blue Grape #1 (CBD) visually leans toward dense, conical buds with tight calyx stacking and visible resin coverage, despite its CBD-forward nature. Mature flowers often exhibit green to blue-green hues, and in cooler grow rooms (night temps dropped into a safe, modest range), anthocyanin expression can push purple and lavender tones. Pistils tend to present in apricot to copper shades, creating contrast that underscores the berry theme.

Trichome density is typically high enough to give a frosted sheen, with a prevalence of capitate-stalked heads that signal robust resin formation. Even in CBD-dominant chemotypes, resin formation can be impressive, often translating to a thicker, velvety hand-feel. Structural internodes suggest indica-leaning bud density on branches, though CBD selections frequently retain some sativa-leaning vigor in vegetative growth.

Trimmed buds usually cure to a medium firmness, with broken nugs releasing immediate sweet-floral notes. Properly handled batches showcase wick-like dryness without brittleness, a sign of correctly balanced moisture content near the industry target of 10–12% after cure. This moisture window helps preserve terpenes while preventing microbial risks.

Aroma and Flavor: Blue-Berry Meets Grape-Floral

On the nose, Blue Grape #1 (CBD) pushes forward sweet berry jam, concord-grape accents, and soft floral tones that hint at linalool and geraniol. Subtler secondary notes can include berry skin tannin, faint citrus zest, and a creamy backnote reminiscent of vanilla bean. Dry pulls often reveal a candy-like quality that persists even with low-temperature inhalation.

The flavor on combustion or vaporization skews toward candied blueberry and grape peel, with a pleasant, cooling floral tail. A gentle spice prickle at the end suggests a caryophyllene contribution, while occasional pine-mint flickers can signal pinene in the blend. Vaping in the 175–190°C band often accentuates floral and fruit notes, whereas hotter settings tilt toward toastier, spicier undertones.

Mouthfeel tends to be smooth and lightly coating, with minimal harshness when properly cured. Consumers often describe a round sweetness that remains apparent even after multiple inhalations. Terpene persistence is a hallmark; many CBD-forward connoisseurs prize cultivars like this for session-length flavor that does not fatigue the palate.

Cannabinoid Profile and Ratios

While batch-specific COAs are essential for certainty, CBD-dominant flower in this category commonly tests at 8–18% CBD by dry weight and 0.1–0.8% THC. Many producers target CBD:THC ratios of 10:1, 15:1, or 20:1 for reliable low intoxication. Ratios above 20:1 are not uncommon in hemp-aligned selections, though sensory richness often correlates with careful breeding and curing rather than the absolute ratio.

In dispensary datasets, the median THC content across adult-use flower SKUs often falls near 20%, whereas CBD-rich SKUs cluster under 1% THC. This contrast explains why consumers sensitive to THC gravitate to cultivars like Blue Grape #1 (CBD). It allows engagement with the cannabis ritual while drastically reducing the probability of THC-driven anxiety or impairment.

Minor cannabinoids can contribute to the experience. CBDV, CBG, and CBC may each appear in trace to low-percentage ranges in CBD-dominant chemotypes, sometimes totaling 0.2–1.5% combined. Although present at lower levels than CBD, these molecules may modulate perceived effects through the entourage hypothesis, an area of active research.

Terpene Profile and Aromatic Chemistry

Blue Grape #1 (CBD) likely leans on a terpene core of myrcene, linalool, and beta-caryophyllene, with supporting pinene, ocimene, or geraniol depending on cut and cultivation. Total terpene content in quality craft flower typically ranges from 1.0–3.5% by weight, with exceptional batches exceeding 4%. This concentration influences both aroma intensity and perceived smoothness on inhalation.

Myrcene is frequently the dominant terpene in many modern cultivars and is associated with musky fruit and relaxation notes. Linalool, common in lavender, adds floral sweetness and is often linked to calming, spa-like aromatic effects. Beta-caryophyllene provides a pepper-spice edge and uniquely acts as a CB2 receptor agonist in vitro, aligning with reports of body-centric ease.

Fruit-specific impressions such as “grape” or “blueberry” are multi-factorial. In cannabis, these impressions are often driven by combinations of linalool, geraniol, alpha-terpineol, and occasionally farnesene or esters formed during curing. Balanced ratios of these compounds can yield the lush, dessert-like bouquet that makes Blue Grape #1 (CBD) especially memorable.

Experiential Effects: Calm, Clarity, and Body Ease

Consumers typically describe Blue Grape #1 (CBD) as relaxing without fogging cognition, with a calm onset that becomes noticeable within minutes of inhalation. The CBD-led profile tends to moderate any residual THC-led euphoria, resulting in stable mood elevation without racing thoughts. Many report a gentle softening of muscle tension and a smoothing of the baseline stress curve.

Because CBD does not bind CB1 strongly, intoxication is usually minimal, particularly when THC remains below 0.8%. Users sensitive to THC often find CBD-dominant cultivars reduce the chance of acute anxiety or short-term tachycardia. The serotonergic and GABAergic pathways implicated in CBD’s broader pharmacology may contribute to perceived tranquility, though subjective responses vary.

Sessions often feel functional: users can read, work on light tasks, or socialize without distortion. A subset of consumers notes mild sedation at higher intake volumes, especially when myrcene or linalool are prominent. For that reason, Blue Grape #1 (CBD) can flex between daytime composure at low-intake and evening wind-down when consumed more liberally.

Safety, Side Effects, and Interactions

CBD is generally well tolerated, but it is not free of side effects. Common mild adverse events include dry mouth, lightheadedness, and, less frequently, GI upset. In higher doses, CBD can cause somnolence; this is more likely with additional sedating terpenes.

CBD interacts with hepatic enzymes (notably CYP3A4 and CYP2C19), which can alter the metabolism of certain medications. Individuals on drugs such as warfarin, clobazam, or some SSRIs should consult a clinician before using CBD products regularly. In clinical epilepsy trials, high-dose CBD (10–20 mg/kg/day) produced meaningful seizure reductions but also increased odds of liver enzyme elevations in a minority of patients.

For inhaled flower, combustion introduces byproducts not present in vaporization; consumers prioritizing respiratory comfort may prefer dry-herb vaporization. Always verify COAs to rule out contaminants such as pesticides, heavy metals, and microbials. Reputable producers publish batch-level results, including cannabinoid potency and terpene profiles.

Potential Medical Uses: What the Evidence Suggests

CBD has the strongest human evidence base in pediatric-onset epilepsies such as Dravet and Lennox–Gastaut syndromes. In randomized trials using purified CBD, median seizure reductions around 37–42% were observed at dosing between 10 and 20 mg/kg/day. While Blue Grape #1 (CBD) is not a medicine, its CBD-dominant profile aligns with a class of products studied for seizure modulation under medical supervision.

Beyond epilepsy, studies suggest CBD may help with certain anxiety presentations, particularly performance or social anxiety, though effect sizes and optimal dosing remain under investigation. Observational data in legal markets indicate many patients use CBD-rich cannabis for chronic pain, inflammatory conditions, and sleep disturbances. In these use-cases, CBD’s safety profile and low intoxication can support daily functioning.

It’s essential to distinguish between whole-flower inhalation and clinical-grade oral CBD. Inhaled delivery produces rapid onset within minutes and shorter duration (often 1–3 hours), whereas oral formats onset slower (30–120 minutes) with longer tails. Patients should coordinate with healthcare providers to tailor formats, especially when combining CBD with prescription medications.

Dosing and Use Considerations (Non-Medical Guidance)

For new users, a “start low and go slow” approach helps calibrate comfort and effect. With CBD-dominant flower, one or two small inhalations can be enough to gauge response, particularly for daytime use. Effects often plateau quickly, allowing users to titrate without overshooting comfort.

People with zero THC tolerance should still check the THC percentage on the COA, as even 0.5–0.8% THC can be perceptible to some. Those especially sensitive might prefer micro-sessions or vaping at lower temperatures to emphasize flavor and comfort. Oral tinctures using the same cultivar’s extract can serve as an alternative, though onset and duration differ.

Consistency comes from standardized products and routines. Keeping a brief log of intake time, amount, and perceived effects can help refine personal dosing. This simple habit can improve outcomes over a few sessions, especially when using CBD to support sleep, stress, or mild muscle tension.

How to Evaluate a Jar: Quality and COA Checkpoints

Start with appearance: look for intact trichomes, healthy green-to-purple hues, and an even hand-trim without excessive leaf. Lightly squeeze for resilience; quality flower should spring back and feel neither brittle nor overly spongy. Aroma should be vivid and distinct, not musty, grassy, or faint.

Next, scan the COA. For a CBD-dominant cultivar like Blue Grape #1 (CBD), expect CBD in the mid-to-high single digits up to the mid-teens percentage by weight, and THC under 1%. Verify absence of common contaminants, and review the terpene readout to confirm a berry-floral profile with linalool/myrcene/caryophyllene features.

Storage matters. Freshness windows are typically best within 3–6 months of packaging when stored in opaque, airtight containers around cool, stable temperatures. Prolonged heat and light exposure can degrade both cannabinoids and terpenes, blunting aroma and altering perceived effects.

Comparisons to Similar CBD-Dominant Strains

Against ACDC, Blue Grape #1 (CBD) tends to showcase a sweeter, dessert-leaning aroma rather than ACDC’s often woody-citrus profile. Where ACDC commonly tests in the 15–20% CBD range with trace THC, Blue Grape #1 (CBD) may sit slightly lower or similar, depending on phenotype and producer. The key differentiator is sensory: grape and blueberry notes versus ACDC’s cr